Abivax shares traded higher after the French biotechnology company said its lead drug candidate achieved durable remission for a bowel disease in a clinical study. Shares in Abivax rose as much as 3.9 ...

For some people, relief can last years. For others, only a few weeks. Learn what to do to stay in remission for as long as possible.

Treatment failure occurs when an ulcerative colitis medication isn’t helping symptoms. Most important, know that it’s not your fault. Learn what to do next.

While some studies suggest CBD oil may help reduce inflammation and provide symptomatic relief for ulcerative colitis, more research is needed to confirm its effectiveness. The FDA has not approved ...

When you find out that you have ulcerative colitis (UC), that explains why you have symptoms like diarrhea and abdominal cramps. But you probably still have questions about things like food, stress, ...

Ulcerative colitis affects only the innermost lining of the bowel. Crohn’s disease, on the other hand, can involve all layers ...

Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD). It causes painful sores and inflammation deep inside your colon and rectum. That can lead to hard-to-manage symptoms like ...

Inflammatory bowel disease (IBD) is an umbrella term for Crohn's disease and ulcerative colitis, which both involve chronic inflammation in the digestive tract. IBD affects millions of people and ...

Unfortunately the cause of ulcerative colitis is unknown, although both genetic and the environmental causes have been proposed. Most patients with ulcerative colitis do not have anyone else in the ...

'Imagine having a wound that never heals. Only it’s on the inside and every time you eat or drink, it’s like rubbing salt into that wound.' When asked to explain the sensation of ulcerative colitis, ...

Being diagnosed with ulcerative colitis (UC) can be stressful and a bit scary. A type of autoimmune condition, UC is an inflammatory bowel disease that affects between 600,000 and 900,000 Americans, ...

Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients ...